DE60009315D1 - Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung - Google Patents
Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlungInfo
- Publication number
- DE60009315D1 DE60009315D1 DE60009315T DE60009315T DE60009315D1 DE 60009315 D1 DE60009315 D1 DE 60009315D1 DE 60009315 T DE60009315 T DE 60009315T DE 60009315 T DE60009315 T DE 60009315T DE 60009315 D1 DE60009315 D1 DE 60009315D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- dewanning
- cyamemazine
- symptoms
- benzodiazepine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 title abstract 2
- 229940049706 benzodiazepine Drugs 0.000 title abstract 2
- SLFGIOIONGJGRT-UHFFFAOYSA-N cyamemazine Chemical compound C1=C(C#N)C=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 SLFGIOIONGJGRT-UHFFFAOYSA-N 0.000 title 1
- 229960004278 cyamemazine Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9910472A FR2797399B1 (fr) | 1999-08-13 | 1999-08-13 | Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines |
FR9910472 | 1999-08-13 | ||
PCT/FR2000/002186 WO2001012265A1 (fr) | 1999-08-13 | 2000-07-28 | Utilisation de la cyamemazine dans le traitement du sevrage brutal aux benzodiazepines |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60009315D1 true DE60009315D1 (de) | 2004-05-13 |
DE60009315T2 DE60009315T2 (de) | 2005-02-17 |
Family
ID=9549128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60009315T Expired - Lifetime DE60009315T2 (de) | 1999-08-13 | 2000-07-28 | Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung |
Country Status (12)
Country | Link |
---|---|
US (1) | US6534500B2 (de) |
EP (1) | EP1212119B1 (de) |
JP (1) | JP5078209B2 (de) |
AT (1) | ATE262362T1 (de) |
AU (1) | AU6846300A (de) |
CA (1) | CA2381354C (de) |
DE (1) | DE60009315T2 (de) |
DK (1) | DK1212119T3 (de) |
ES (1) | ES2214305T3 (de) |
FR (1) | FR2797399B1 (de) |
PT (1) | PT1212119E (de) |
WO (1) | WO2001012265A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1626727B1 (de) * | 2003-02-07 | 2008-12-31 | Aventis Pharmaceuticals Inc. | Verwendung von 2-cyano-10- (2-methyl-3- (methylamino)- propyl)-phenothiazin oder einem pharmazeutisch akzeptablen salz davon als arzneimittel |
FR2850871B1 (fr) * | 2003-02-07 | 2006-07-14 | Aventis Pharma Sa | Application du 2-cyano-10-(2-methyl-3-(methylamino)propyl) phenothiazine ou un sel pharmaceutiquement acceptable comme medicament |
US7855196B2 (en) * | 2005-08-22 | 2010-12-21 | Pierre Mainville | Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist |
DE102011078999A1 (de) | 2011-07-12 | 2013-01-17 | Carl Zeiss Sms Gmbh | Verfahren und Vorrichtung zur Positionsbestimmung von Strukturen auf einer Maske für die Mikrolithographie |
DE102013101445B9 (de) | 2013-02-14 | 2022-01-05 | Carl Zeiss Smt Gmbh | Verfahren zur Ermittlung von Verzeichnungseigenschaften eines optischen Systems in einer Messvorrichtung für die Mikrolithographie |
DE102013106320B9 (de) | 2013-06-18 | 2021-07-01 | Carl Zeiss Smt Gmbh | Verfahren zur Ermittlung von Verzeichnungseigenschaften eines optischen Systems in einer Messvorrichtung für die Mikrolithographie |
DE102013107976B4 (de) | 2013-07-25 | 2016-07-28 | Carl Zeiss Sms Gmbh | Positionsbestimmung von Strukturen auf einer Maske für die Mikrolithographie |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE552557A (de) * | 1955-11-15 | |||
US4666903A (en) * | 1985-08-13 | 1987-05-19 | Yale University | Novel use of benzodiazepine antagonist |
FR2654621B1 (fr) | 1989-11-22 | 1994-09-23 | Esteve Labor Dr | Inhibition du syndrome d'abstinence. |
CA2112487C (en) * | 1991-06-26 | 2003-04-15 | James W. Young | Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron |
IL123716A (en) * | 1997-03-27 | 2001-03-19 | Akzo Nobel Nv | Therapeutic combinations of mirtazapine and an antipsychotic agent |
JP2001517223A (ja) | 1997-04-02 | 2001-10-02 | バイオニケ ライフ サイエンシーズ インコーポレイテッド | 原生動物性または寄生生物性疾患の予防、治療または排除のための細菌細胞壁抽出物の使用 |
-
1999
- 1999-08-13 FR FR9910472A patent/FR2797399B1/fr not_active Expired - Fee Related
-
2000
- 2000-07-28 ES ES00956565T patent/ES2214305T3/es not_active Expired - Lifetime
- 2000-07-28 JP JP2001516607A patent/JP5078209B2/ja not_active Expired - Fee Related
- 2000-07-28 EP EP00956565A patent/EP1212119B1/de not_active Expired - Lifetime
- 2000-07-28 PT PT00956565T patent/PT1212119E/pt unknown
- 2000-07-28 CA CA002381354A patent/CA2381354C/en not_active Expired - Lifetime
- 2000-07-28 DK DK00956565T patent/DK1212119T3/da active
- 2000-07-28 AT AT00956565T patent/ATE262362T1/de active
- 2000-07-28 AU AU68463/00A patent/AU6846300A/en not_active Abandoned
- 2000-07-28 WO PCT/FR2000/002186 patent/WO2001012265A1/fr active Search and Examination
- 2000-07-28 DE DE60009315T patent/DE60009315T2/de not_active Expired - Lifetime
-
2002
- 2002-02-11 US US10/073,436 patent/US6534500B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ES2214305T3 (es) | 2004-09-16 |
US6534500B2 (en) | 2003-03-18 |
PT1212119E (pt) | 2004-07-30 |
WO2001012265A1 (fr) | 2001-02-22 |
JP2003507352A (ja) | 2003-02-25 |
CA2381354A1 (fr) | 2001-02-22 |
CA2381354C (en) | 2008-12-30 |
AU6846300A (en) | 2001-03-13 |
JP5078209B2 (ja) | 2012-11-21 |
FR2797399A1 (fr) | 2001-02-16 |
US20020183332A1 (en) | 2002-12-05 |
DK1212119T3 (da) | 2004-06-21 |
EP1212119A1 (de) | 2002-06-12 |
FR2797399B1 (fr) | 2002-10-18 |
ATE262362T1 (de) | 2004-04-15 |
DE60009315T2 (de) | 2005-02-17 |
EP1212119B1 (de) | 2004-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE316785T1 (de) | Jak-3 hemmer zur behandlung von allergischen störungen | |
BR0011130A (pt) | Inibidores de metaloproteases | |
ATE340171T1 (de) | Piperazinderivate zur behandlung bakterieller infektionen | |
DE60023043T2 (de) | (S,S)-Reboxetin zur Behandlung von Inkontinenz | |
DE60032795D1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
ATE380548T1 (de) | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie | |
ATE337780T1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
DE60019555D1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
SE9802208D0 (sv) | Novel compounds | |
ATE271865T1 (de) | Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen | |
DE69711078D1 (de) | Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz | |
ATE319473T1 (de) | Melagatran zur behandlung von entzündungen | |
ATE418552T1 (de) | Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
UY26426A1 (es) | Nuevos compuestos | |
SE9902267D0 (sv) | New compounds | |
DE60036122D1 (de) | Verwendung von eplerenon zur behandlung von restenose | |
DE60009315D1 (de) | Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung | |
PT1000046E (pt) | Derivados de piperazina activos no trato urinario inferior | |
ATE330599T1 (de) | Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
ATE261724T1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen | |
BG105984A (bg) | Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението | |
ATE267194T1 (de) | Medikamente geeignet zur behandlung von proliferativen erkrankungen | |
DE50010972D1 (de) | UBICHINON Qn ZUR BEHANDLUNG VON MIGRÄNESCHMERZEN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN |
|
8328 | Change in the person/name/address of the agent |
Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC |